Regeneron Pharmaceuticals Inc. buy Canaccord Genuity Group Inc.
Summary
This prediction ended on 22.08.24 with a price of €1,060.5. With a performance of 39.08% the BUY prediction by Canaccord_Genuity_Gr was a big success. Canaccord_Genuity_Gr has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. Canaccord_Genuity_Gr has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 1.360% | 1.360% | 42.407% |
| iShares Core DAX® | -0.874% | 5.325% | 6.865% |
| iShares Nasdaq 100 | -0.381% | 1.979% | 25.696% |
| iShares Nikkei 225® | -1.676% | 1.952% | 41.443% |
| iShares S&P 500 | -0.655% | 2.069% | 21.405% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.
Current prediction by Canaccord_Genuity_Gr for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
19.05.26
19.05.27
18:18

